(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of 91.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.31%, and while it is forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Meiragtx Holdings's revenue in 2026 is $27,417,000.On average, 9 Wall Street analysts forecast MGTX's revenue for 2026 to be $14,304,840,793, with the lowest MGTX revenue forecast at $473,286,427, and the highest MGTX revenue forecast at $23,333,503,812. On average, 5 Wall Street analysts forecast MGTX's revenue for 2027 to be $11,453,048,596, with the lowest MGTX revenue forecast at $2,603,075,350, and the highest MGTX revenue forecast at $20,790,796,629.
In 2028, MGTX is forecast to generate $17,033,481,930 in revenue, with the lowest revenue forecast at $8,862,851,788 and the highest revenue forecast at $31,106,508,963.